Regulatory factors are perhaps one of the most important things for any healthcare company and if it is to find consistent success, then those factors have to be managed well. This brings us to the subject of Halberd Corporation (OTC:HALB), which is in the news this morning on the back of some vital announcement with regards to its regulatory affairs. Investors are reacting positively this morning with a jump of over 6% to $0.0180.
The company came into focus this morning after it emerged that it had hired the services of the firm mdi Consultants Inc for the purposes of getting assistance with the convoluted application and certification procedures at the United States Food and Drug Administration.
The consultancy firm is going to help Halberd with regard to the testing and application processes. In addition to that, mdi will also Halberd with complete guidance related to the disclosure that will have to be made and the documents that will have to be filed throughout the different stages. Halberd had been engaged in many rounds of discussion with representatives from mdi and the company has noted that it is confident that mdi is the correct choice in this particular endeavor. It goes without saying that engaging mdi is a major development for the company and reflects how seriously Halberd takes the entire regulatory process.
The executive vice president at mdi, Alan Schwartz, spoke about the development as well. He noted that mdi was looking forward to taking Halberd Corporation’s technology through the FDA regulatory process. He went on to add that mdi has been working in this field for as long as 44 years and during that period it has been successful in guiding as many as 4000 products and devices through the review process that is in place at FDA. It now remains to be seen if the latest development has an effect on the Halberd stock or not.
